

### *Supplementary Findings*

At baseline, 48% of patients (46% assigned to 50 mg QD and 50% assigned to 100 mg BID) had cough frequency at baseline  $\geq 10$ /hour while awake. This subgroup's median (IQR) cough frequency at baseline was greater for 50 mg QD [25.6 (20.8–36.1)] than for 100 mg BID [18.5 (14.5–33.7)]. There was a reduction in objective cough rates for these patients at week 24 (–31.7% versus –3.8%) for 50 mg QD and 100 mg BID, respectively. Sixteen patients (nine patients: 50 mg QD, seven patients: 100 mg BID) experienced a >30% decrease in objective cough at week 24. Eleven patients (five patients: 50 mg QD, six patients: 100 mg BID) experienced a >30% increase in objective cough at week 12 or week 24. Five (one patient: 50 mg QD, four patients: 100 mg BID) of the 11 patients had an accompanying respiratory AE or infection, including thrush, respiratory tract infection, dyspnoea, and worsening of IPF, and one patient had a cough AE.